Cargando…

Berberine Improves Irinotecan-Induced Intestinal Mucositis Without Impairing the Anti-colorectal Cancer Efficacy of Irinotecan by Inhibiting Bacterial β-glucuronidase

Irinotecan (CPT11), a broad-spectrum cytotoxic anticancer agent, induces a series of toxic side-effects. The most conspicuous side-effect is gastrointestinal mucositis, including nausea, vomiting, and diarrhea. A growing body of evidence indicates that bacteria β-glucuronidase (GUS), an enzyme expre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yue, Bei, Gao, Ruiyang, Lv, Cheng, Yu, Zhilun, Wang, Hao, Geng, Xiaolong, Wang, Zhengtao, Dou, Wei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8593678/ https://www.ncbi.nlm.nih.gov/pubmed/34795594 http://dx.doi.org/10.3389/fphar.2021.774560

Ejemplares similares

Microbiota-Host-Irinotecan Axis: A New Insight Toward Irinotecan Chemotherapy
por: Yue, Bei, et al.
Publicado: (2021)

Systematic evaluation of irinotecan-induced intestinal mucositis based on metabolomics analysis
por: Yu, Qing-Qing, et al.
Publicado: (2022)

Entropy-driven binding of gut bacterial β-glucuronidase inhibitors ameliorates irinotecan-induced toxicity
por: Lin, Hsien-Ya, et al.
Publicado: (2021)

Herbal Medicines for Irinotecan-Induced Diarrhea
por: Tang, Liu, et al.
Publicado: (2019)

Synergistic Effects of Simvastatin and Irinotecan against Colon Cancer Cells with or without Irinotecan Resistance
por: Jang, Hyun Joo, et al.
Publicado: (2016)

Irinotecan toxicity: genes or intestinal microflora?
por: Brandi, G, et al.
Publicado: (2009)

Newly Obtained Apple Pectin as an Adjunct to Irinotecan Therapy of Colorectal Cancer Reducing E. coli Adherence and β-Glucuronidase Activity
por: Palko-Łabuz, Anna, et al.
Publicado: (2021)

Berberine Attenuates Intestinal Mucosal Barrier Dysfunction in Type 2 Diabetic Rats
por: Gong, Jing, et al.
Publicado: (2017)

Simultaneous inhibition of ATR and PARP sensitizes colon cancer cell lines to irinotecan
por: Abu-Sanad, Atlal, et al.
Publicado: (2015)

Dissecting Target Toxic Tissue and Tissue Specific Responses of Irinotecan in Rats Using Metabolomics Approach
por: Yao, Yiran, et al.
Publicado: (2017)

Quantitative Evaluation of the Compatibility Effects of Huangqin Decoction on the Treatment of Irinotecan-Induced Gastrointestinal Toxicity Using Untargeted Metabolomics
por: Cui, Dong-Ni, et al.
Publicado: (2017)

The Adaptor Protein Myd88 Is a Key Signaling Molecule in the Pathogenesis of Irinotecan-Induced Intestinal Mucositis
por: Wong, Deysi V. T., et al.
Publicado: (2015)

Irinotecan-Induced Dysarthria
por: Dressel, Albertine J., et al.
Publicado: (2012)

ABCB1 Genetic Variants as Predictors of Irinotecan-Induced Severe Gastrointestinal Toxicity in Metastatic Colorectal Cancer Patients
por: Riera, Pau, et al.
Publicado: (2020)

Irinotecan-gut microbiota interactions and the capability of probiotics to mitigate Irinotecan-associated toxicity
por: Mahdy, Marwa S., et al.
Publicado: (2023)

Therapeutic Dose Response of Acoustic Cluster Therapy in Combination With Irinotecan for the Treatment of Human Colon Cancer in Mice
por: Bush, Nigel, et al.
Publicado: (2019)

Induction cisplatin–irinotecan followed by concurrent cisplatin–irinotecan and radiotherapy without surgery in oesophageal cancer: multicenter phase II FFCD trial
por: Michel, P, et al.
Publicado: (2006)

Prior irinotecan exposure does not preclude benefit to liposomal irinotecan in patients with metastatic pancreatic ductal adenocarcinoma
por: Yu, Kenneth H., et al.
Publicado: (2023)

Activation of PXR by Alpinetin Contributes to Abrogate Chemically Induced Inflammatory Bowel Disease
por: Yu, Zhilun, et al.
Publicado: (2020)

Effects of methimazole on the elimination of irinotecan
por: van der Bol, Jessica M., et al.
Publicado: (2010)

Inflammatory Bowel Disease: A Potential Result from the Collusion between Gut Microbiota and Mucosal Immune System
por: Yue, Bei, et al.
Publicado: (2019)

Irinotecan-containing doublet treatment versus irinotecan monotherapy as second-line choice for advanced gastric cancer
por: Yang, Liuting, et al.
Publicado: (2018)

The novel tankyrase inhibitor (AZ1366) enhances irinotecan activity in tumors that exhibit elevated tankyrase and irinotecan resistance
por: Quackenbush, Kevin S., et al.
Publicado: (2016)

Shengjiang Xiexin Decoction Alters Pharmacokinetics of Irinotecan by Regulating Metabolic Enzymes and Transporters: A Multi-Target Therapy for Alleviating the Gastrointestinal Toxicity
por: Guan, Huan-yu, et al.
Publicado: (2017)

Triple-Regimen of Vemurafenib, Irinotecan, and Cetuximab for the Treatment of BRAF(V600E)-Mutant CRC: A Case Report and Review
por: Cho, Su Min, et al.
Publicado: (2021)

Irinotecan Upregulates Fibroblast Growth Factor Receptor 3 Expression in Colorectal Cancer Cells, Which Mitigates Irinotecan-Induced Apoptosis()()
por: Erdem, Zeynep N., et al.
Publicado: (2017)

Soluble HLA-G expression levels and HLA-G/irinotecan association in metastatic colorectal cancer treated with irinotecan-based strategy
por: Scarabel, Lucia, et al.
Publicado: (2020)

Sphingomyelin Liposomes Containing Porphyrin-phospholipid for Irinotecan Chemophototherapy
por: Carter, Kevin A, et al.
Publicado: (2016)

Irinotecan-Induced Steatohepatitis: Current Insights
por: Han, Jun, et al.
Publicado: (2021)

Irinotecan (CPT-11) Chemotherapy Alters Intestinal Microbiota in Tumour Bearing Rats
por: Lin, Xiaoxi B., et al.
Publicado: (2012)

Improved Progression-Free Survival in Irinotecan-Treated Metastatic Colorectal Cancer Patients Carrying the HNF1A Coding Variant p.I27L
por: Labriet, Adrien, et al.
Publicado: (2017)

EGCG Enhances the Chemosensitivity of Colorectal Cancer to Irinotecan through GRP78-MediatedEndoplasmic Reticulum Stress
por: Wu, Wenbing, et al.
Publicado: (2022)

Irinotecan Monotherapy Versus Irinotecan-Based Combination as Second-Line Chemotherapy in Advanced Gastric Cancer: A Meta-Analysis
por: Cho, Yo-Han, et al.
Publicado: (2017)

Knockdown of TRIM9 attenuates irinotecan-induced intestinal mucositis in IEC-6 cells by regulating DUSP6 expression via the P38 pathway
por: Zhao, Wenjun, et al.
Publicado: (2021)

EGCG synergizes the therapeutic effect of irinotecan through enhanced DNA damage in human colorectal cancer cells
por: Wu, Wenbing, et al.
Publicado: (2021)

Extended RAS Analysis of the Phase III EPIC Trial: Irinotecan + Cetuximab Versus Irinotecan as Second‐Line Treatment for Patients with Metastatic Colorectal Cancer
por: Sobrero, Alberto, et al.
Publicado: (2020)

Cellular irinotecan resistance in colorectal cancer and overcoming irinotecan refractoriness through various combination trials including DNA methyltransferase inhibitors: a review
por: Ozawa, Shogo, et al.
Publicado: (2021)

Formulation and Evaluation of Irinotecan Suppository for Rectal Administration
por: Feng, Haiyang, et al.
Publicado: (2014)

Population Pharmacokinetics of Liposomal Irinotecan in Patients With Cancer
por: Adiwijaya, BS, et al.
Publicado: (2017)

Irinotecan-Induced Serpentine Supravenous Hyper-Pigmentation
por: Gaurav, Vishal, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kidqu1focifmpukjj40o91ll41